Why Shell and BP Shares Aren't Surging Is a Mystery to me. But You Might Want to Invest in Case the Dam Bursts
GlaxoSmithKline (GSK) has announced second quarter of the year results, including stating “strong commercial execution” and “we are likely to deliver full-year Adjusted EPS towards the better end of our guidance range”. So where now for the shares?, with they currently having responded back up to 1400p.
FTSE-100 pharma and healthcare company GlaxoSmithKline (GSK) is currently engaged in somewhat of a battle with well known activist investor Elliott Advisors. However, that is about the level of change as change is coming and Elliott is only involved as it “believes GSK has a substantial value creation opportunity – 45% upside in its share price – ahead of Consumer Health separation and greater beyond”. We concur that there is an attractive value creation opportunity here...
Earlier this year – a week or two after I published an article on the British multinational pharmaceutical company GlaxoSmithKline (GSK) HERE, I bought shares in the FTSE 100 giant for the first time in well over a decade. It has worked out pretty well so far, but the story is certainly evolving because - as I noted here in early May - ‘GlaxoSmithKline is fortunately about so much more than the current CEO’. I am sure you have heard about the ‘strategic overhaul of GlaxoSmithKline by Dame Emma Walmsley’ which was announced yesterday.
I turned positive - for the first time in years and years - on GlaxoSmithKline (GSK) shares back in February here. I noted back then that my optimism was based on much more than cheapish EV:ebit ratios and alright free cash flow generation (and the dividend paid). As I noted again here a few weeks back, “Hedge fund Elliott builds up multibillion-pound stake in GSK” because the anticipation that GlaxoSmithKline will split out some of its business is set to happen over the next year and this will create extra value.
First I see that GlaxoSmithKline (GSK) shares were nicely firm yesterday. As I noted here back in mid-February I could see an opportunity to buy the shares...which I did later on that month. Yesterday’s move was driven by an article - planted in the FT - which noted that "Hedge fund Elliott builds up multibillion-pound stake in GSK...Activist group’s investment comes as UK drugmaker's performance lags rivals".
Hello, Share Tasters. It’s been a while since I’ve looked at GlaxoSmithKline (GSK). It’s the big British rival of AstraZeneca (AZN). Though it’s lost out in the publicity stakes associated with a covid vaccine, Glaxo should still benefit from a heightened interest in all things medical.
I have not been a fan of GlaxoSmithKline (GSK) shares for a long time now but if you pick up its chart today, you will see the stock kicking around at a new five year low. So what to think about a name that used to be a FTSE 100 favourite...and is even actively trying to finalise a Covid-19 vaccine product?
Hello Share Chasers. Many of us will be trying out short-term plays on speculative shares in these volatile days. With shares up and down a lot, you may even be tempted into a bit of day trading. However, my 24-hour trades nearly always become long-term investments as the hoped for daily hike hardly ever happens. Not to me anyway. So let’s look at a share which, if held long enough, could be a strong winner...
Hello, Share Breakers. As I’ve suggested before, pharmaceutical companies, both gigantic and small, could benefit from the heightened interest in all health matters. And I would guess that the one that comes up with a vaccine for COVID-19 might do even better. So which companies are looking for a vaccine?...
Assuming that you aren’t just going to move entirely to cash and wait for the markets to bottom and show signs of a rebound before buying anything, there are still some options for shares to hold whilst you ride out the storm.
Hello, Share Dibbers. The jumbo pharma GlaxoSmithKline (GSK) is undergoing changes. And if you think the company is making the right decisions, then then you might consider a closer look. The City has been pleased with the latest quarter results and though my own holding has not risen much over the years, perhaps that could change now...
Hello Share Peekers. A Footsie jumbo which I have shares in, but rarely write about, is GlaxoSmithKline (GSK).To give you an idea of its size, it’s the fourth biggest outfit in the Footsie. And while it's true the big fish can flounder, like the former British Energy, for example, we can hope for a measure of security not inherent in smaller companies.
Hello Share Trudgers. Though treading in my erudite colleague Chris Bailey’s shoes, I thought it might be useful to have another take on GlaxoSmithKline (GSK) This giant pharma is a big part of my ‘safer’ Footsie portfolio (I put safer in quotes as some of my biggest losses ever have been members of the big 100 club)...
Hello, Share Whackers. My more inspirational Shareprophets colleague Chris Bailey has already posted on an exciting development for GlaxoSmithKline (GSK). As this is a share I’ve also pushed for some years, allow me to add my own humble thoughts...
Much has been said or written about GlaxoSmithKline (GSK) during 2018 and my most recent contribution back in July suggested that a divisional split-up was a spoof. Well today's announcement that Glaxo has formed a joint venture vehicle with US pharma behemoth Pfizer for their respective consumer health arms (with ownership split 68%/32% in favour of Glaxo) appears at face value like a step in the right direction for under pressure CEO Emma Walmsley and team…
Hello, Share Pinchers. One of the most attractive sectors to invest in for those who like to inhabit the moral high ground is medicine. Who would not want to try to alleviate pain and suffering in Britain and the world? Yes, there can be worries that some companies are not as good as they might be in curbing the costs of treatment and drugs, but on the whole it’s a satisfying area of investment.
Last week I hoped that GlaxoSmithKline's (GSK) backing away from a mega deal which would have seen them splurge US$20bn odd on the consumer unit of American pharma name Pfizer was an early sign of a new commitment to not building an empire and maybe even considering splitting the company up into its constituent parts. Well that slammed that door closed today with news that they are buying out the shares in a consumer healthcare jv they have with the Swiss pharma giant Novartis for a cool US$13 billion.
The Mail on Sunday headline says it all " Brexit fears are diverting cash from vital cancer battle say drug firms." That sod Boris Johnson and the witch Priti Patel - now they are causing more cancer patients to die. Bastards! Er....
The big pharmaceutical companies have traditionally been a fairly safe bet for a steady source of income over the years, and through the peaks and troughs in the markets.
Hello Share Shapers. Every so often I look at that great British pharmaceutical giant, GlaxoSmithKline (GSK) and I usually notch it up as a buy. Despite the fact that it has not been quite as successful a punt as I had hoped, I am still well up on my three year old purchase. The dividend, which I have at nearly 5% is also useful. And I was gratified that it was one of the perkiest Footsie risers on Friday.
Hello Share Punchers. I’ve just heard on the BBC more woes facing British hospitals. It does seem that most of them now have no slack and routine operations keep being put off, with nowhere to send many patients once beyond the surgeon’s knife.
It is great to see that one of the UK's largest companies, GlaxoSmithKline (GSK) has a new CEO who has a cracking CV and and has without doubt been appointed on merit. Oh... and she wears a skirt, that is to say that she is a woman, Emma Walmsley. I wish her well. Emma demonstrates a couple of things which will horrify the liberal left.
With uncertainty over Brexit and possible market turmoil around this event, and assuming you’re not planning to move to cash, now would seem like a good time to add some defensive shares to your portfolio.
I hope you have a happy and healthy New Year. Though, especially if you are of a certain age, I fear the odds are against it. My Christmas cards usually contain letters from old friends and relatives. And I was shocked to learn that one of them had almost lost her sight, another is on crutches awaiting knee transplants, another has breast cancer and so on.
Hello Share Trippers. Oh dear! The price of crude oil drops to less than 40 dollars a barrel.That’s really nasty and we can blame OPEC for refusing to cut down on the amber nectar it has for sale.
The recent big drops in many leading stock market indices, including the FTSE100, is giving an opportunity to pick some stocks up at a bargain price. I think that GlaxoSmithKline (GSK) definitely falls into that category and its current share price of around 1285p – the lowest levels since mid-2011 – offers a great long term buying opportunity for this FTSE100 listed pharmaceutical company.
After some careful thought I have selected GlaxoSmithKline (GSK) as one of just two of my Prime Share Selections for 2015. Being honest, I find it difficult to pick two which really should be the best of all shares, but I am fairly confident GlaxoSmithKline will perform well in 2015.
GlaxoSmithKline (GSK) has recently announced that it has failed to sell its established products portfolio. This is basically a bunch of North American and European drugs that have recently lost their patent protection.
Hello Share Pounders. At the risk of sounding again like a soft goody goody (TW Note - perish the thought), I want to commend to you the warm feeling that can be achieved by investing in big pharma companies.
It’s been a torrid year for GlaxoSmithKline’s (GSK) share price. From a year high of 1706p, it recently fell to a low of 1296.p. However there was some much needed cheer yesterday, when the shares, trading at around 1330p, were lifted to over 1400p briefly, before closing at 1385.5p. The catalyst? Publication of its results at 12 o’clock which beat expectations.
Ebola is certainly everywhere on the news at the moment. The epidemic continues to spread like wildfire, and more people are dying all the time. Thankfully, GlaxoSmithKline (GSK) is continuing its work on a vaccine which should help stem the spread. Today it issued a press statement, opening with the following:
The FTSE took quite a hit yesterday. It closed down by 1.04% at 6495.58. Yet there is good news- I believe there are a number of buying opportunities around at the moment! For the long term investor a general market sell off should be viewed as an opportunity not a cause for alarm. So here are two stocks that I am nowlooking to add to thanks to the market wobble.
GlaxoSmithKline (GSK) shares are currently trading at 1457p on a PE of 13.1 and a dividend yield of 5.35%. I’ve only fairly recently bought into the company, here is a table at between 1379p and 1556.6p, So I am not exactly quids in yet but this is a long term play.
The fall in the GlaxoSmithKline (GSK) share price to1428p is a story in its self. Not only is it back to where it approximately was in 2013 but it now stands on what I perceive to be a three year support level. (Have a look for yourselves.) If so, will the share price hold there and is it a reason to buy the shares as cheap at 1428p on an historic dividend yield of 5.4% and on the basis that “there will always be a Glaxo”; an approach that has generally speaking been a good point to buy the shares when the news looks bleakest?
Hello Share Fans: I'm in a strange position for me. I have a few thousand quid in my ISA which I need to invest. I think I might take a look at GlaxoSmithKline (GSK).
The latest information and news emerging from GlaxoSmithKline (GSK) is of encouragement to investors generally but to dividend investors most particularly. Although the company is one of the stock markets dividend yield staple, with a long established reputation for cash generation, a glance at the trends in its cash flow statements is a bit disconcerting.
Medical matters are on my mind as I have the Norovirus. But it takes more than that to stop me writing about companies but naturally my mind turns to drugs. Well I was a young man in the sixties – the 1960s not the 1860s before you ask. Talking of ancient history, the market long ago abandoned the assumption that GlaxoSmithKline (GSK) would automatically build a pathway for shareholders to a starlight future of endless profits and earnings growth, by simply spending 15% of its sales revenue on R&D, and turning that into an approved blockbuster therapy every few years. In truth, costs rose and progress became more difficult – the return on R&D capital was not acceptable.
Search ShareProphets |
Recent Comments |